Sitagliptin
Sitagliptin was the first dipeptidyl peptidase-4 (DPP-4) inhibitor approved for type 2 diabetes in the United States, approved in 2006. It works by preserving the activity of natural incretin hormones to enhance insulin secretion and reduce glucagon. It is well tolerated, weight-neutral, and carries a low risk of hypoglycemia.
Sitagliptin is a DPP-4 inhibitor used to improve blood sugar control in type 2 diabetes. It works by blocking the enzyme that breaks down incretin hormones, prolonging their action to stimulate insulin release and suppress glucagon after meals.
Uses & FDA Indications
Sitagliptin is indicated exclusively for type 2 diabetes. It is used as monotherapy or in combination with other antidiabetic agents.
FDA-Approved Uses
- Type 2 diabetes mellitus — adjunct to diet and exercise to improve glycemic control in adults, as monotherapy or in combination with metformin, sulfonylureas, thiazolidinediones, or insulin
Not Approved For
- Type 1 diabetes mellitus
- Diabetic ketoacidosis
- Cardiovascular or renal protection (unlike SGLT2 inhibitors and GLP-1 agonists, DPP-4 inhibitors have neutral cardiovascular outcomes; the TECOS trial showed non-inferiority but no superiority for CV events)
How It Works
Incretin hormones — particularly GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) — are released from the gut after meals. They stimulate insulin secretion from the pancreas and suppress glucagon in a glucose-dependent manner. However, these hormones are rapidly broken down by the enzyme dipeptidyl peptidase-4 (DPP-4), limiting their activity to just 1–2 minutes after release.
Sitagliptin inhibits DPP-4, extending the active lifetime of GLP-1 and GIP. This amplifies the natural postmeal insulin response and reduces inappropriate glucagon secretion — both of which lower blood glucose. Because the effect is glucose-dependent (incretins only stimulate insulin when glucose is elevated), the risk of hypoglycemia is inherently low when sitagliptin is used without insulin or sulfonylureas.
Sitagliptin is primarily renally excreted. About 79% of the drug is excreted unchanged in urine, requiring dose adjustment in patients with kidney disease.
Side Effects
Common
- Nasopharyngitis (runny nose, sore throat) and upper respiratory tract infections
- Headache
- Nausea and stomach upset (generally mild)
- Hypoglycemia — only when combined with insulin or sulfonylureas
- Urinary tract infections
Serious
- Pancreatitis — acute and sometimes fatal; reported across the DPP-4 inhibitor class; discontinue if suspected
- Severe joint pain (arthralgia) — FDA warning for disabling joint pain across all DPP-4 inhibitors; may occur weeks to years after starting; resolves with discontinuation
- Heart failure — the SAVOR-TIMI 53 trial with saxagliptin (a related drug) showed increased heart failure hospitalizations; the TECOS trial with sitagliptin did not show this signal, but clinicians remain cautious in patients with heart failure
- Hypersensitivity reactions — anaphylaxis, angioedema, and SJS reported; rare
- Bullous pemphigoid — blistering skin disease; class-wide association with DPP-4 inhibitors
PANCREATITIS WARNING: Cases of acute pancreatitis, including fatal hemorrhagic or necrotizing pancreatitis, have been reported with DPP-4 inhibitors including sitagliptin. If pancreatitis is suspected, discontinue sitagliptin promptly. Patients with a history of pancreatitis should use sitagliptin with caution.
Drug Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Insulin and sulfonylureas (glipizide, glyburide, glimepiride) | Additive glucose-lowering effect; increased hypoglycemia risk when combined with insulin-secretagogues | Moderate — reduce insulin or sulfonylurea dose when adding sitagliptin; monitor blood glucose |
| Digoxin | Sitagliptin modestly increases digoxin plasma concentrations (~11%); may be more relevant in patients at the upper end of the therapeutic range | Low–Moderate — monitor digoxin levels and symptoms of toxicity |
| Cyclosporine | P-glycoprotein inhibition by cyclosporine increases sitagliptin exposure significantly | Moderate — monitor for sitagliptin side effects; may need dose adjustment |
| Other antidiabetic drugs (metformin, thiazolidinediones, SGLT2 inhibitors) | Additive glucose lowering; combinations are commonly used and generally safe; hypoglycemia risk remains low unless insulin or a sulfonylurea is also included | Low — well-tolerated combinations; monitor glucose |
| Corticosteroids (prednisone, dexamethasone) | Corticosteroids raise blood glucose; may reduce the efficacy of sitagliptin and other antidiabetics | Moderate — monitor blood glucose during steroid courses; temporary insulin coverage may be needed |
| ACE inhibitors | Both sitagliptin and ACE inhibitors affect bradykinin metabolism; potential for additive angioedema risk | Low–Moderate — report any facial or airway swelling immediately |
| Thiazide diuretics | Raise blood glucose, reducing glycemic efficacy of antidiabetic agents | Low–Moderate — monitor HbA1c; titration adjustment may be needed |
Warnings & Contraindications
Sitagliptin is contraindicated in patients with a history of serious hypersensitivity reactions to sitagliptin (anaphylaxis, angioedema, exfoliative skin conditions). It should not be used in type 1 diabetes or for DKA treatment. Dose adjustment is required in renal impairment.
Key Precautions
- Pancreatitis: Use caution in patients with a history of pancreatitis; discontinue immediately if acute pancreatitis is suspected
- Joint pain: Educate patients about the possibility of severe, disabling arthralgia; if it occurs, stopping sitagliptin typically resolves it
- Renal impairment: Dose reduction required based on eGFR; monitor kidney function periodically
- Heart failure: Although sitagliptin's TECOS data are reassuring, caution is warranted in patients with established heart failure; consider SGLT2 inhibitors or GLP-1 agonists (which have proven CV benefits) in high-risk patients
- Bullous pemphigoid: Report any blistering skin rash — may require dermatology evaluation and discontinuation
Frequently Asked Questions
Does sitagliptin cause weight gain?
No — sitagliptin is considered weight-neutral. Unlike sulfonylureas or insulin (which cause weight gain) or SGLT2 inhibitors and GLP-1 agonists (which cause weight loss), DPP-4 inhibitors have minimal effect on body weight. This makes sitagliptin an attractive option for patients who are concerned about weight or who have not responded well to weight-gaining agents.
How does sitagliptin compare to GLP-1 agonists like semaglutide?
Both sitagliptin and GLP-1 agonists work through the incretin system, but GLP-1 agonists (semaglutide, liraglutide, dulaglutide) directly activate GLP-1 receptors at much higher levels than physiological, producing stronger HbA1c reductions, significant weight loss, and proven cardiovascular and renal benefits. Sitagliptin modestly raises natural GLP-1 levels by blocking its breakdown, providing a gentler and well-tolerated effect but without the weight loss or proven organ-protective benefits. GLP-1 agonists are now preferred over DPP-4 inhibitors in most high-risk patients.
Can sitagliptin be used in kidney disease?
Yes, with dose adjustment. Unlike metformin (which is contraindicated in severe kidney disease) and some other antidiabetic agents, sitagliptin can be used even in significant renal impairment — including patients on dialysis — at appropriately reduced exposures. The dose reduction requirement is based on eGFR thresholds. This makes sitagliptin a useful option for patients with CKD who have limited antidiabetic choices.
What does DPP-4 stand for?
DPP-4 stands for dipeptidyl peptidase-4, also known as CD26 — a cell-surface enzyme that rapidly cleaves and inactivates the incretin hormones GLP-1 and GIP. By blocking this enzyme, sitagliptin prevents the breakdown of these hormones, allowing them to work longer to stimulate insulin and suppress glucagon in a glucose-dependent way. The "gliptin" suffix used for all drugs in this class (sitagliptin, saxagliptin, linagliptin, alogliptin) reflects their shared mechanism.
Need to identify a pill? Use the PillID visual search tool.
Identify a Pill →